Teriflunomide: all 29 studies that test it

Page 1 of 1. Open to participants first (4), then studies with results posted, then the rest; newest registration first within each.

• The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2)RecruitingNCT07065968Phase 2
• Teriflunomide for Steroid-resistant/Relapse Immune ThrombocytopeniaRecruitingNCT06190145Phase 2
• The Combination of Teriflunomide and Danazol for Steroid-resistant/Relapse Immune ThrombocytopeniaRecruitingNCT06176911Phase 2
• Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic ParaparesisRecruitingNCT04799288Phase 1/2
• Rapid Elimination Procedure of Teriflunomide With Colestipol HydrochlorideTerminatedNCT02263547Phase 1Results posted
• Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple SclerosisCompletedNCT02201108Phase 3Results posted
• MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCVCompletedNCT01970410Phase 4Results posted
• Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) PatientsCompletedNCT01895335Phase 4Results posted
• Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on TeriflunomideCompletedNCT01403376Phase 2Results posted
• Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-betaTerminatedNCT01252355Phase 3Results posted
• Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple SclerosisCompletedNCT00811395Phase 2Results posted
• Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple SclerosisCompletedNCT00803049Phase 3Results posted
• An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple SclerosisCompletedNCT00751881Phase 3Results posted
• Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple SclerosisCompletedNCT00622700Phase 3Results posted
• Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple SclerosisCompletedNCT00489489Phase 2Results posted
• Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple SclerosisCompletedNCT00475865Phase 2Results posted
• Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple SclerosisCompletedNCT00134563Phase 3Results posted
• Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune ThrombocytopeniaWithdrawnNCT06176235Phase 2
• Teriflunomide vs. Placebo During Gluten Challenge in Celiac DiseaseCompletedNCT04806737Phase 1/2
• Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 WeeksCompletedNCT04410965Phase 4
• Teriflunomide Concentration in Serum and Cerebrospinal Fluid From Patients With Multiple SclerosisCompletedNCT04129736Phase 4
• To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple SclerosisCompletedNCT03856619Phase 4
• Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated SyndromeCompletedNCT03122652Phase 3
• A Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension PeriodCompletedNCT02587195Phase 3
• A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese VolunteersCompletedNCT02046629Phase 1
• Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple SclerosisCompletedNCT01863888Phase 3
• Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With RelapsesCompletedNCT01487096Phase 2
• Pharmacokinetic and Tolerability Study of 14 mg Single Dose of Teriflunomide in Subjects With Severe Renal ImpairmentCompletedNCT01239459Phase 1
• Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With RelapsesCompletedNCT00228163Phase 2

← Teriflunomide overview